IL6 and amyotrophic lateral sclerosis: More recently, a multicenter, prospective study enrolling 101 participants found that, beyond a remarkable reduction in plasma IL-6 concentration, the 28-day mortality of COVID patients in the ALS group (16%) was significantly lower than that of the control group (50.98%), suggesting that ALS treatment could block cytokine storm and reduce short-term mortality (61).